Cite
Douthwaite J, Moisan J, Privezentzev C, et al. Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. J Immunol. 2017;199(5):1943doi: 10.4049/jimmunol.1790013.
Douthwaite, J., Moisan, J., Privezentzev, C., Soskic, B., Sabbah, S., Cohen, S., Collinson, A., England, E., Huntington, C., Kemp, B., Zhuang, L., Hudak, S., Rees, D. G., Goldberg, D., Barton, C., Chang, L., Vainshtein, I., Liang, M., Iciek, L., Ambery, P., Peakman, M., Vaughan, T. J., Tree, T. I. M., Sansom, D. M., Bowen, M. A., Minter, R. R., & Jermutus, L. (2017). Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. Journal of immunology (Baltimore, Md. : 1950), 199(5), 1943. https://doi.org/10.4049/jimmunol.1790013
Douthwaite, Julie, et al. "Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding." Journal of immunology (Baltimore, Md. : 1950) vol. 199,5 (2017): 1943. doi: https://doi.org/10.4049/jimmunol.1790013
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR, Jermutus L. Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. J Immunol. 2017 Sep 01;199(5):1943. doi: 10.4049/jimmunol.1790013. PMID: 28827388.
Copy
Download .nbib
